Phase 2 Trial of a Low Dose, Bedtime, Proprietary Sublingual Formulation of Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Mediators and Moderators of Treatment Response

Presented at the Military Health System Research Symposium (MHSRS) in Kissimmee, FL August 27-30; MHSRS-17-1685 Poster Session 2 - Poster #521, 10:00 AM - 4:30 PM EDT, Florida Exhibit Hall D-F

Gregory M. Sullivan, Helen Stillwell, Florence Porterfield, Judy Gendreau, R. Michael Gendreau, Ashild Peters, Perry Peters, Seth Lederman

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

Poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami, FL on June 1, 2017

Gregory Sullivan, Judy Gendreau, R Michael Gendreau, Jean Engels, Perry Peters, Ashild Peters, Seth Lederman

Bedtime Sublingual Transmucosal Cyclobenzaprine (TNX-102 SL) for the Treatment of Military-Related PTSD: Retrospective Analyses of the Mediators and Moderators of Treatment Response

Poster presented at the Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP) in Miami, FL on June 1, 2017

Gregory Sullivan, Judy Gendreau, R Michael Gendreau, Jean Engels, Perry Peters, Ashild Peters, Seth Lederman

Phase 2 Multisite Double-Blind Placebo-Controlled Trial of TNX-102 SL* in Military-Related Posttraumatic Stress Disorder (PTSD): Mediators and Moderators of Treatment Response

Poster presented at the 72nd Annual Scientific Convention of the Society of Biological Psychiatry in San Diego, CA on May 20, 2017

Gregory Sullivan, Judy Gendreau, R Michael Gendreau, Jean Engels, Perry Peters, Ashild Peters, Seth Lederman

The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX - 102 SL* in the Treatment of Military - Related P TSD

Poster presented at the 55th Annual Meeting of the American College of Neuropsychopharmacology in Hollywood, FL, December 7, 2016

Gregory Sullivan, Judy Gendreau, R Michael Gendreau, Amy Schaberg, Bruce Daugherty, Heather Jividen, Ashild Peters, Perry Peters, Frank Weathers, Seth Lederman

Low-Dose Sublingual Cyclobenzaprine (TNX-102 SL*) in Military-Related PTSD: Results of a Phase 2 Randomized, Placebo-Controlled Multicenter Trial

Poster Presented at the International Society for Traumatic Stress Studies 32nd Annual Meeting in Dallas, TX, November 10, 2016

Gregory M. Sullivan, Judith F. Gendreau, R. Michael Gendreau, Amy Schaberg, Bruce L. Daugherty, Heather Jividen, Ashild Peters, Perry Peters, Seth Lederman

The Efficacy and Safety of TNX-102 SL, a Sublingual Formulation of Cyclobenzaprine, for the Treatment of Military-Related PTSD.

Poster Presented at the 2016 NEI Psychopharmacology Congress in Colorado Springs, CO, November 3-6, 2016

Gregory Sullivan, Judith Gendreau, R. Michael Gendreau, Amy Schaberg, Bruce Daugherty, Heather Jividen, Ashild Peters, Perry Peters, Seth Lederman

A Retrospective Analysis of the Efficacy of TNX-102 SL in Military-Related PTSD:
Determining the Appropriate Severity Threshold for Trial Entry Using the Clinician-Administered PTSD Scale for DSM-5

Poster Presented at the CNS Summit 2016 in Boca Raton, Florida, October 27-30, 2016

Gregory M. Sullivan, Perry Peters, R. Michael Gendreau, Judith F. Gendreau, Ashild Peters, Jean M. Engels, Amy Schaberg, Heather Jividen, Seth Lederman

Tonix PTSD Awareness Day - October 26, 2016
Dr. Seth Lederman – Welcome and Introduction

Tonix PTSD Awareness Day - October 26, 2016
Dr. Jonathan Davidson – A Review of Pharmacotherapy for PTSD